Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
tetravalent dengue VLP vaccine
- Development stage
- Preclinical
- Lead developer
- VLP Therapeutics
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The **tetravalent dengue VLP vaccine** is a non-replicating virus-like particle (VLP)-based vaccine candidate designed to protect against all four dengue virus serotypes (DENV1-4). Developed by **VLP Therapeutics** using their proprietary VLP platform, it presents equal quantities of structural antigens (prM and E proteins) from each serotype to induce balanced, high-titer neutralizing antibodies without antibody-dependent enhancement (ADE), a key safety concern for dengue vaccines. Preclinical studies in non-human primates demonstrated robust humoral immunity, reduced viral replication upon challenge, and protection via IgG transfer in mice; it shows promise for safe use in immunocompromised individuals and is advancing toward clinical evaluation for dengue prevention.[2][4][6]
- Other names
- DENVLP vaccine
02
Targets
DENV-1 E (Dengue virus serotype 1 envelope protein)DENV-2 E (Dengue virus serotype 2 envelope protein)DENV-3 E (Dengue virus serotype 3 envelope protein)DENV-4 E (Dengue virus serotype 4 envelope protein)
Beyond the preview
Go deeper on tetravalent dengue VLP vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on tetravalent dengue VLP vaccine.